-
May 16, 2013
Novo Nordisk's chief executive Lars Rebien Sorensen has accused politicians in some European countries of making empty promises to their populations in terms of access to innovative drugs and called for more harmonisation of regulatory systems across the globe
Full story
-
May 01, 2013
Novo Nordisk has posted yet another stellar set of figures, helped by strong sales of its diabetes drug Victoza
Full story
-
April 23, 2013
UK group Kymab has entered into an agreement with Danish drug giant Novo Nordisk to discover novel therapeutic antibodies.
Full story
-
March 19, 2013
Novo Nordisk saw its shares slip 4% after its stock was downgraded and a higher dose of its insulin drug liraglutide failed to greatly impress on weight loss scores in a late-stage clinical trial.
Full story
-
March 14, 2013
Diabetes firm becomes newest member of the ABPI as negotiations into VBP enter their final stage
Full story
-
February 13, 2013
Sanofi has unveiled a 44 million euro investment at its facility in Waterford, Ireland, to help meet escalating demand for its long-acting basal insulin Lantus
Full story
-
February 12, 2013
Novo Nordisk has suffered a huge blow after US regulators refused to approve its new insulin Tresiba.
Full story
-
February 01, 2013
Novo Nordisk has posted another stellar set of figures for the fourth quarter, helped by strong sales of diabetes drug Victoza and its modern insulins
Full story
-
January 22, 2013
Novo Nordisk is celebrating after European regulators gave the green light to Tresiba and Ryzodeg, which the Danish company hopes will challenge Sanofi's Lantus, the world's biggest-selling insulin product
Full story
-
November 09, 2012
Shares in Novo Nordisk have soared this morning after an FDA panel recommended approval of Tresiba and Ryzodeq, despite expressing concerns over possible cardiovascular risk of the ultra long-acting insulins
Full story